Kidney Transplant Outcomes Similar With Hep C+ Donors
At 1 year after transplant, kidney allograft function, rejection rates similar regardless of donor hepatitis C status.
Hepatitis C
Controversy: Protecting People Who Use Drugs During COVID-19
Anna Lembke, MD, discusses how patients who use drugs are affected by the convergence of 2 public health emergencies – increasing overdose rates, and the COVID-19 pandemic – and addresses controversial solutions proposed by other investigators.
Despite Hepatitis C Virus Status, Many Positive Liver Allograft Donors Were Healthier and Younger
Increased utilization of HCV-positive liver allografts for LT is seen as one of the ways to counter national organ shortages, so researchers set out to better characterize the allografts that come from HCV-positive donors from specific regions.
Hepatocellular Carcinoma May Present at Earlier Stage of Liver Disease in Black Patients With HCV
Investigators evaluated the incidence of HCC in the absence of cirrhosis in Black patients with HCV.
American College of Physicians Updates Best Practice Advice for Chronic HCV
Based on guidelines issued by the World Health Organizations in 2018, the American College of Physicians has issued best practice advice that simplifies and improves treatment of chronic hepatitis C virus.
Liver Stiffness Post HCV Anti-Viral Therapy Associated With Several Adverse Outcomes
Measuring liver stiffness should be considered after anti-viral treatment because it predicts adverse outcomes even beyond routinely available clinical predictors.
Glecaprevir/Pibrentasvir Effective in Wide Range of Frail HCV Subpopulations
Italian investigators conducted a prospective, multicenter study to assess the safety and effectiveness of glecaprevir/pibrentasvir in chronic hepatitis C patients and their subpopulations.
Hepatitis C-Negative Patients Receive Positive Kidney Transplants
A study published in the Annals of Internal Medicine found transplanting kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative recipients (HCV D+/R-) may be successful with prophylactic treatment with direct-acting antivirals.
Cost-Effectiveness of Universal and Targeted Hepatitis C Screening
Researchers conducted a simulated economic evaluation cohort analyses to assess the cost-effectiveness of HCV screening and compared other screening programs in the United States.
Safety, Efficacy of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naive HCV Examined
Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.
-
Loading...
-
Loading...
Next post in Hepatitis
